Abstract：
OBJECTIVE: While several studies reported epidermal growth factor receptor (EGFR) expression in salivary gland cancer (SGC), results varied due to a lack of unified definition of EGFR positivity. In this study, we assessed the EGFR expression level using both EGFR positive score and cumulative EGFR score in the patients with SGC.
METHODS: Between January 2010 and April 2021, 102 patients with SGC who underwent surgical resection were reviewed retrospectively by immunohistochemistry. The membrane staining intensity was scored as follows: no staining (0), weak staining (1+), intermediate staining (2+), and strong staining (3+). The cumulative EGFR score was determined on a continuous scale of 0-300 using the formula:1 × (1+: percentage of weakly stained cells) + 2 × (2+: percentage of moderately stained cells) + 3 × (3+: percentage of strongly stained cells).
RESULTS: EGFR expression in SGC varied widely even among the same as well as different histopathological types. The average EGFR positive scores were 46.0 %, 55.7 %, 51.6 %, 1.0 %, 26.8 %, 50 %, and 76.8 % for mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (AcCC), adenocarcinoma NOS (ACNOS), carcinoma ex pleomorphic adenoma (CAexPA), and squamous cell carcinoma (SqCC), respectively. The average cumulative EGFR scores were 82, 91, 80, 1, 52, 93, and 185 for MEC, SDC, AdCC, AcCC, ACNOS, CAexPA, and SqCC, respectively.
CONCLUSIONS: EGFR positive scores and cumulative EGFR scores in SGCs varied among the various histological types, and even in the same histological type. These scores may predict the clinical outcome of SGC treated with EGFR-targeting therapies, such as head and neck photoimmunotherapy, and need to be evaluated in future studies.
METHODS: Between January 2010 and April 2021, 102 patients with SGC who underwent surgical resection were reviewed retrospectively by immunohistochemistry. The membrane staining intensity was scored as follows: no staining (0), weak staining (1+), intermediate staining (2+), and strong staining (3+). The cumulative EGFR score was determined on a continuous scale of 0-300 using the formula:1 × (1+: percentage of weakly stained cells) + 2 × (2+: percentage of moderately stained cells) + 3 × (3+: percentage of strongly stained cells).
RESULTS: EGFR expression in SGC varied widely even among the same as well as different histopathological types. The average EGFR positive scores were 46.0 %, 55.7 %, 51.6 %, 1.0 %, 26.8 %, 50 %, and 76.8 % for mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (AcCC), adenocarcinoma NOS (ACNOS), carcinoma ex pleomorphic adenoma (CAexPA), and squamous cell carcinoma (SqCC), respectively. The average cumulative EGFR scores were 82, 91, 80, 1, 52, 93, and 185 for MEC, SDC, AdCC, AcCC, ACNOS, CAexPA, and SqCC, respectively.
CONCLUSIONS: EGFR positive scores and cumulative EGFR scores in SGCs varied among the various histological types, and even in the same histological type. These scores may predict the clinical outcome of SGC treated with EGFR-targeting therapies, such as head and neck photoimmunotherapy, and need to be evaluated in future studies.
摘要：
目的：虽然一些研究报道了唾液腺癌（SGC）中表皮生长因子受体（EGFR）的表达，由于缺乏EGFR阳性的统一定义,结果各不相同.在这项研究中,我们使用EGFR阳性评分和EGFR累积评分评估了SGC患者的EGFR表达水平.
方法：2010年1月至2021年4月，对102例接受手术切除的SGC患者进行免疫组织化学回顾性分析。膜染色强度评分如下:无染色(0),弱染色（1+），中间染色（2+），和强染色（3+）。使用公式:IX(1+:弱染色细胞的百分比)+2X(2+:中度染色细胞的百分比)+3X(3+:强染色细胞的百分比)在0-300的连续标度上确定累积EGFR得分。
结果：EGFR在SGC中的表达差异很大，即使在相同和不同的组织病理学类型中也是如此。平均EGFR阳性评分为46.0%,55.7%,51.6%,1.0%，26.8%,50%,粘液表皮样癌（MEC）占76.8％，涎管癌（SDC），腺样囊性癌（AdCC），腺泡细胞癌（AcCC），腺癌NOS(ACNOS),多形性腺瘤（CAexPA），鳞状细胞癌（SqCC），分别。MEC的平均累积EGFR评分分别为82、91、80、1、52、93和185。SDC,AdCC,AcCC,ACNOS,CAexPA,和SqCC，分别。
结论：SGC的EGFR阳性评分和累积EGFR评分在不同组织学类型之间有所不同，甚至在相同的组织学类型。这些评分可以预测EGFR靶向治疗的SGC的临床结果。例如头颈部光免疫疗法，并需要在未来的研究中进行评估。
方法：2010年1月至2021年4月，对102例接受手术切除的SGC患者进行免疫组织化学回顾性分析。膜染色强度评分如下:无染色(0),弱染色（1+），中间染色（2+），和强染色（3+）。使用公式:IX(1+:弱染色细胞的百分比)+2X(2+:中度染色细胞的百分比)+3X(3+:强染色细胞的百分比)在0-300的连续标度上确定累积EGFR得分。
结果：EGFR在SGC中的表达差异很大，即使在相同和不同的组织病理学类型中也是如此。平均EGFR阳性评分为46.0%,55.7%,51.6%,1.0%，26.8%,50%,粘液表皮样癌（MEC）占76.8％，涎管癌（SDC），腺样囊性癌（AdCC），腺泡细胞癌（AcCC），腺癌NOS(ACNOS),多形性腺瘤（CAexPA），鳞状细胞癌（SqCC），分别。MEC的平均累积EGFR评分分别为82、91、80、1、52、93和185。SDC,AdCC,AcCC,ACNOS,CAexPA,和SqCC，分别。
结论：SGC的EGFR阳性评分和累积EGFR评分在不同组织学类型之间有所不同，甚至在相同的组织学类型。这些评分可以预测EGFR靶向治疗的SGC的临床结果。例如头颈部光免疫疗法，并需要在未来的研究中进行评估。
